EMS subsidiary Brace Pharma Capital returned to help HPV therapy developer Antiva Biosciences increase its overall funding to $57m.

Osage University Partners has returned to back a series C1 round for Antiva, which is developing treatments for HPV and is based on research at UC San Diego.

The healthtech investment firm has closed a $188m third fund featuring several care providers and insurers as limited partners.

The biopharmaceutical company, which was co-founded by Ionis Pharmaceuticals, has secured funding in an Andera Partners-led round.

Andera Partners has led a $55m funding round for Dynacure, co-founded by Satt Conectus to commercialise research from the Institute of Genetic and Molecular and Cellular Biology.

Essence Group Holdings, the owner of care services provider Lumeris, has formed a partnership with new strategic investor Cerner.

The Leap Fund will back early-stage, risky research that would not be able to secure funding through other channels.

Gunilla Lundmark has been hired as managing director of Uppsala University Holding, succeeding founding chief executive Lars Jonsson.

Unternehmertum Venture Capital Partners has agreed to sell its shares in AMW as part of an acquisition led by Hybio Pharmaceutical and Yunfeng Capital.